Advances and Novel Concepts in Herpesvirus Vaccines
A special issue of Viruses (ISSN 1999-4915). This special issue belongs to the section "Viral Immunology, Vaccines, and Antivirals".
Deadline for manuscript submissions: 31 May 2024 | Viewed by 3941
Special Issue Editors
Interests: KSHV; influenza virus; MHV-68; vaccines; interferons
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
We are planning a Special Issue on “Advances and Novel Concepts in Herpesvirus Vaccines”. Herpesviruses are responsible for extensive morbidity and mortality on a worldwide basis. Vaccines are the most effective method of protecting individuals against diseases caused by herpesvirus infections, as demonstrated by the Oka vaccine based on live attenuated varicella-zoster virus that has drastically reduced chickenpox and varicella-related deaths. More recently, an adjuvanted recombinant gE subunit vaccine, Shingrix, was developed to prevent shingles. Herpesviruses have relatively large genomes and alternate from lytic to latent phases of infection. Alpha- and betaherpesviruses cause diseases via lytic replication, whereas cancers associated with gammaherpesviruses are composed of mostly latently infected cells, where expression of latency-associated genes from the viral genome predisposes cells to transformation by driving the proliferation of infected cells. A large repertoire of immune evasion genes and the ability to enter latency increase the challenge for herpesvirus vaccine development. Nevertheless, considerable advancements have been made regarding the efficacy of different vaccine platforms and immune correlates of protection against infection and disease. We would like to invite scientists to share their recent research progress on herpesvirus vaccines in this Special Issue.
Dr. Ting-Ting Wu
Dr. Laurie T. Krug
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Viruses is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- herpesvirus
- vaccines
- antibody
- T-cell
